Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01794507 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT01794507 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 66 participants.
The verdict
NCT01794507, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
The primary objectives of this study are to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and the recommended phase two dose (RPTD) of ABT-199 when administered in subjects with relapsed /refactory multiple myeloma who are receiving bortezomib and dexamethasone as their standard therapy.
Interventions
- DRUG dexamethasone
- DRUG bortezomib
- DRUG ABT-199
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2012-11-19 |
| Est. Completion | 2019-07-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01794507
The ClinicalTrials.gov registry entry for NCT01794507 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which dexamethasone is the first listed.
NCT01794507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01794507 about?
NCT01794507 is a clinical study titled "A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy". The primary objectives of this study are to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and the recommended phase two dose (RPTD) of ABT-199 when administered in subjects with relapsed /refactory multiple myeloma who ...
What is the current status of trial NCT01794507?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2012-11-19. Estimated completion is 2019-07-16.
What interventions are being tested in trial NCT01794507?
The interventions under investigation include: dexamethasone (DRUG), bortezomib (DRUG), ABT-199 (DRUG).
Who is sponsoring clinical trial NCT01794507?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.